Table 5. Correlation analysis of miRNA expressions in needle biopsies and clinicopathological data of 49 patients, who have been treated for local PCa with curatively intended retropubic prostatectomy.
| miRNA | Test | Prebiopsy PSA | GS (NB) | GS (RRP) | pT | D’Amico | NCCN |
|---|---|---|---|---|---|---|---|
| miRNA-21 |
rho P-value |
-0.065 0.677 |
0.107 0.496 |
0.071 0.653 |
0.104 0.508 |
0.169 0.279 |
0.133 0.397 |
| miRNA-34a |
rho P-value |
0.124 0.425 |
-0.171 0.267 |
0.150 0.332 |
0.031 0.841 |
0.102 0.511 |
0.084 0.589 |
| miRNA-125b |
rho P-value |
-0.145 0.355 |
-0.188 0.226 |
-0.135 0.390 |
-0.312 0.042 |
-0.149 0.339 |
-0.080 0.608 |
| miRNA-126 |
rho P-value |
-0.089 0.572 |
-0.019 0.905 |
0.088 0.574 |
-0.041 0.795 |
0.125 0.424 |
0.075 0.633 |
| miRNA-143 |
rho P-value |
0.023 0.883 |
-0.071 0.650 |
0.170 0.277 |
-0.004 0.982 |
0.013 0.935 |
-0.094 0.548 |
| miRNA-145 |
rho P-value |
-0.059 0.7038 |
0.204 0.1840 |
0.016 0.9197 |
-0.057 0.713 |
0.181 0.240 |
0.123 0.427 |
D’Amico: D’Amico Risk Profile; GS: Gleason score; NB: Needle biopsy; NCCN: National Comprehensive Cancer Network; P-values are from Spearman's rho test; PSA: Prostate specific antigen; pT: Pathological T-stage; RRP: Retropubic radical prostatectomy.